| A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma (NCT07684287) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2026-08-01 |
| Evaluation of Bioequivalence and Food Effect of a New Strength Formulation of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Participants. (NCT07756996) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2026-07-15 |
| SYH2095 for Advanced Malignant Tumors: Phase I Study (NCT07692776) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2026-07-01 |
| A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly (NCT07623824) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2026-05-31 |
| A Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function (NCT07694869) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2026-05-10 |
| A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants (NCT07532655) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2026-04-14 |
| A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and Normal Liver Function (NCT07694843) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2026-03-30 |
| A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 (NCT07412353) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2026-01-12 |
| Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer (NCT07282509) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-12-23 |
| A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT07418736) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-12-18 |
| A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors (NCT07241936) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-11-13 |
| HB1801 Combined Treatment of HER2-positive Breast Cancer (NCT07116824) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-09-15 |
| A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type) (NCT07163364) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-08-31 |
| Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (NCT07165886) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-08-29 |
| A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer (NCT07083505) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-08-15 |
| Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors (NCT06947291) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-06-04 |
| Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases (NCT07117435) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-05-13 |
| A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer (NCT06941142) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-04-30 |
| Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors (NCT06929325) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-04-01 |
| A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis (NCT06688435) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-03-04 |
| The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (NCT06827431) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-02-14 |
| A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients (NCT06771245) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2025-01-24 |
| A Study of SYS6020 Injection in Refractory Active Systemic Lupus Erythematosus (NCT06694298) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-12-26 |
| A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (NCT06547333) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-09-13 |
| A Study of Docetaxel for Injection (Albumin Bound) in Patients With Advanced Pancreatic Cancer (NCT06492941) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-08-12 |
| A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET) (NCT06505395) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-07-30 |
| A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer (NCT06525350) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-07-01 |
| A Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects (NCT07508462) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-05-30 |
| DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer (NCT06313086) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-03-13 |
| A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (NCT06296706) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-02-27 |
| Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus (NCT06161844) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2024-02-23 |
| A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. (NCT06136988) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-12-01 |
| A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer (NCT06011291) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-08-15 |
| Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (NCT05875428) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-07-10 |
| DP303c in Patients With HER2-positive Advanced Breast Cancer (NCT05901935) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-07-01 |
| A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT05863325) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-06-27 |
| A Study of CM326 in Subjects With Moderate to Severe Asthma (NCT05774340) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-05-18 |
| Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain (NCT06379165) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-05-17 |
| A Study of CM310 in Subjects With Moderate to Severe Asthma (NCT05761028) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-04-28 |
| A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors (NCT05810103) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-04-06 |
| A Single-dose Study of Octreotide Injection in Healthy Adult Subjects (NCT05761431) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-03-02 |
| The Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (NCT05762458) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-02-28 |
| Food-effect Study of Ammoxetine Hydrochloride Enteric-coated Tablets (NCT07508501) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-02-08 |
| Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) (NCT05715840) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-01-31 |
| A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer (NCT05705635) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-01-13 |
| Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer (NCT05720026) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-01-09 |
| A Study of Docetaxel for Injection (Albumin-bound) in Patients With Pancreatic Cancer (NCT05616494) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-12-06 |
| A Study of Safety and Efficacy of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumor (PEComa) (NCT05625919) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-11-08 |
| A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI (NCT05475717) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-10-20 |
| A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors (NCT05508620) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-10-01 |
| A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors (NCT05508659) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-09-20 |
| A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer (NCT05325229) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-08-18 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors (NCT05478785) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-08-01 |
| To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors (NCT05407909) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-07-27 |
| A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More (NCT05439824) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-06-28 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia (NCT05345938) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-06-14 |
| A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Older Adults. (NCT05354063) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-06-01 |
| A Study to Evaluate the Effect of Different Meal Types on the Pharmacokinetics of DBPR108 in Healthy Subjects (NCT05150626) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-05-29 |
| DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer (NCT05334810) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-05-01 |
| A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Adults Aged 18 -59 Years. (NCT05354089) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-04-27 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors (NCT05344742) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-04-01 |
| A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor (NCT05089461) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-03-07 |
| Study of HA121-28 in Patients With Non-Small Cell Lung Cancer (NCT05117658) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-02-18 |
| A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors (NCT05114915) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-01-07 |
| A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients (NCT05146869) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-12-30 |
| A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT05055791) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-12-29 |
| A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors (NCT05125523) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-12-28 |
| A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever (NCT05108545) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-12-15 |
| A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML) (NCT05100303) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-12-01 |
| Mass Balance and Biotransformation Study of [14C]DBPR108 in Human (NCT05072028) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-11-16 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced Pancreatic Cancer (NCT05100329) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-11-01 |
| A Study to Evaluate the Drug-drug Interactions (DDIs) of DBPR108 With Warfarin Sodium, Digoxin, Probenecid in Healthy Subjects (NCT05045313) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-10-20 |
| A Study to Evaluate Relative Bioavailability and Food-Effect of HA121-28 Tablet B in Healthy Subjects (NCT05072535) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-10-08 |
| A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) (NCT05068141) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-10-01 |
| A Study of SKLB1028 in Patients With Advanced Solid Tumor (NCT05072522) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-10-01 |
| Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor (NCT05009966) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-09-16 |
| Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC (NCT04983550) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-09-01 |
| SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (NCT05445154) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-08-31 |
| Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (NCT05018013) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-08-21 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma (NCT04900766) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-08-11 |
| A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects (NCT05369858) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-08-06 |
| Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer (NCT04826107) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-08-01 |
| Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer (NCT04886700) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-07-31 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors (NCT04921878) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-07-30 |
| A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) (NCT04787328) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-07-13 |
| Study of DP303c Injection in Patients With Advanced Ovarian Cancer (NCT04828616) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-07-01 |
| A Study of SYHA1805 in Healthy Subjects (NCT04977570) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-07-01 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers (NCT04902027) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-07-01 |
| A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Renal Impairment (NCT04859439) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-06-15 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer (NCT04927481) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-06-11 |
| A Study to Investigate the Drug-drug Interactions (DDIs) Between SKLB1028 and Midazolam in Healthy Subjects (NCT05070195) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-06-07 |
| A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC (NCT04331743) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-06-05 |
| A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects (NCT04859452) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-05-26 |
| The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere (NCT04811118) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-05-18 |
| A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects (NCT05109663) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-04-14 |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL (NCT04668690) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-04-13 |
| A Study of TG103 in Subjects With Type 2 Diabetes (NCT04790006) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-04-01 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma (NCT04718402) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-03-30 |
| A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated (NCT04716114) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-03-24 |
| A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Solid Tumor (NCT04719065) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-01-13 |